Biocon arm's growth formula: US rollouts & debt reduction

Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ModbxCQ
via IFTTT